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Abstract
Background: Breast cancer (BC) represents one of the
leading causes of cancer related deaths worldwide.
New tools for diagnostic staging and therapeutic mon-
itoring are needed to improve individualized therapies
and improve clinical outcome. The analyses of circu-
lating tumour cells may provide important prognostic
information in the clinical setting.
Materials and Methods: Circulating tumour cells
(CTC) of 63 BC patients were isolated from peripheral
blood (PB) through immunomagnetic separation. Sub-
sequently, RT-PCR or mPCR for the genes ga733.2,
muc-1, c-erbB2, mgb-1, spdef and c-erbB2 were performed.
Subsequently, expression data were correlated with the
tumour stages. Fourteen healthy individuals served as
controls.
Results: Significant correlations with tumour stages
were found in single gene analyses of ga733.2, muc-1
and in multi-gene analyses of ga733.2/muc-1/mgb1/
spdef. Furthermore, a significant correlation of Ca 15-3
and all studied genes was also observed.
Conclusion: Herein, we demonstrated a positive corre-
lation of a gene signature consisting of ga733.2, muc-1,
mgb1 and spdef and advanced stages of BC. Moreover,
all studied genes and gene patterns revealed a signifi-
cant correlation with Ca 15-3 positive cases.
Key words: Mamma carcinoma, gene signature, real-
time-PCR
Abbreviations: BC = breast cancer; CTC = circulating
tumour cells; PB = peripheral blood; c-erbB2 = cellular
avian erythroblastosis homologue B2; ga733.2 = major
gastrointestinal tumour-associated protein; muc-1 =
mucin-1; mgb-1 = mammaglobin-typ1; mRNA = mes-
senger RNA; PCR = polymerase chain reaction; RT-
PCR = reverse transcriptase polymerase chain reac-
tion; RT = reverse transcriptase; spdef = SAM pointed
domain-containing ETS transcription factor; FD =
First Diagnosis; MD = Metastatic disease
INTRODUCTION
Even though new developments in clinical research on
breast cancer (BC) have provided clinicians with a set
of important diagnostic tools, there is still an urgent
need for further, more sensitive staging techniques. Re-
cent studies have shown that quantitative and qualita-
tive analyses of circulating tumour cells (CTC) may
provide prognostic information in BC [1, 2]. Attempts
to isolate CTC in peripheral blood (PB) date back to
more than 100 years [3]. Sandberg et al. isolated CTC
from BC patients using centrifugation and fibrinogen
to aggregate erythrocytes [4]. Notably, Hsieh et al. re-
ported that the absolute count of CTC may be related
to an aggressive course of disease in BC patients [5].
First attempts to isolate CTC through immunomagnet-
ic separation were made by Berois et al using a CK-19
on BC cell lines [6]. This technique was recently suc-
cessfully used by Hardingham et al. in patients with
gastrointestinal neoplasias [7]. Combining immuno-
magnectic separation and real-time-PCR (RT-PCR),
this group could positively correlate the presence of
CTC in PB with shorter disease-free intervals.
Gene profile analyses of certain putative genetic
markers may lead to sensitive and specific CTC detec-
tion and may enable an improvement in the outcome
prediction [8-13]. In fact, PCR and RT-PCR can be ap-
plied to perform expression analyses of immunomag-
nectically isolated CTC. In a previous study we
analysed the CTC of 63 BC patients in various disease
stages and identified the genes ga733.2, muc-1, mgb1
and spdef as putative markers for CTC detection. Based
upon our previous data, in this study we performed
correlation analyses between the detected gene expres-
sion levels and the known clinical staging of breast
cancer. Furthermore, we compared the gene expres-
sion data with the detected Ca15-3 serum levels. In-
creased serum levels of the tumour marker Ca 15-3
have been associated with advanced disease and poor
outcome in several studies [14, 15].
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Our study population consisted of 63 BC patients and
14 healthy controls. 50 patients with first diagnosed
disease (FD) and 13 patients with metastatic disease
(MD) in various disease stages were enrolled. All
patients provided written informed consent. After
peripheral venous blood sampling, CTC were separat-
ed using an immunomagnetic method (Adnagen
Breast Cancer Select Kit) according to the instruc-
tions of the manufacturer (Adnagen). Cell lysates
underwent mRNA isolation and reverse transcription
following the manufacturer's instructions (Promega).
Subsequently, mPCR for the genes ga733.2 and
muc-1 and RT-PCR for the genes mgb1 and spdef were
performed. The resulting gene profiles were then
compared with tumour stage according to the TNM
grading system and tumour stage of the American
Joint Committee on Cancer (AJCC) [16]. Additionally,
CTC profiling was compared to ELISA-determined
Ca 15-3 positivity. Correlations were performed either
by Pearson’s two-sided χ2-test for dichotomized val-
ues or by Pearson’s bivariate correlation for values
with two thresholds. Significance was defined by p
< 0.05.
RESULTS
CORRELATION TO DISEASE STATE
Single gene expression and gene patterns were corre-
lated to first diagnosed disease (FD) and metastatic
disease (MD). Only mgb1 was significantly correlated
to MD (p = 0.019) but not to FD, whereas spdef,
muc-1, ga733.2 and c-erbB2 did not correlate with dis-
ease stage. Consecutive multiple gene evaluations
demonstrated significance for the pattern ga733.2/
muc-1 (p = 0.045). The gene pattern ga733.2/muc-
1/spdef/mgb1 showed a significant correlation with
MD (p = 0.023).
CORRELATION TO TUMOUR STAGE
Tumour stage was specified according to AJCC guide-
lines [16]. Since the tumour stage could not be identi-
fied in two BC cases, these patients were excluded
from the study. Single positivity within the gene pat-
tern ga733.2/muc-1 was significantly related to ad-
vanced disease, with 10 out of 12 positive cases found
in level IIIa or higher. Similarly, 11 out of 15 single
positive results within the gene pattern ga733.2/
muc-1/mgb1/spdef were observed in level IIIa or higher.
Finally, 90% (9 out of 10) of twofold-positive results
within the 4 gene pattern were documented in higher
levels (p = 0.001) (Table 1).
CORRELATION TO NODAL STATUS
The gene expression profiles were further correlated
with nodal status. Lymph node (N) status was not
available in 4 patients. They were excluded from fur-
ther analyses. N status was stratified in three levels,
N0, N1 and ≥ N2. Significant correlation was found
between ga733.2 (p = 0.042) and muc-1 (p = 0.039)
overexpression and higher N-levels. The analyses of
spdef, mgb1, ga733.2 and muc-1 did not reveal a signifi-
cant correlation. Interestingly, two-fold positive results
within the gene pattern ga733.2/muc-1/mgb1/spdef were
significant (p = 0.016), whereas simple positive results
within this gene pattern did not correlate with nodal
status (Table 2).
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Table 1. Correlation to disease staging. Correlation between gene expression and disease staging. Patients were stratified in
groups I, IIa-IIb and IIIa or higher. Simple and twofold positivity of the gene profile ga733.2/muc-1/mgb1/spdef are shown
(Pearson’s bivariate correlation).
Analyzed gene Disease Staging
p p- -v va al lu ue e I I I II Ia a- -I II Ib b > >   I II II Ia a
g ga a7 73 33 3. .2 2 0/18 1/16 7/27
% 6.3% 25.9% 0.009
m mu uc c- -1 1 0/18 1/16 9/27
% 6.3% 33.3% 0.002
s sp pd de ef f 0/17 2/15 5/25
% 13.3% 20% 0.057
m mg gb b1 1 0/16 1/15 4/23
% 6.7% 17.4% 0.063
g ga a7 73 33 3. .2 2/m mu uc c- -1 1 0/18 2/16 10/27
% 12.5% 37% 0.001
simple positive 0/16 4/15 11/23
% 26.7% 47.8% 0.001
twofold positive 0/16 1/15 9/23
% 6.7% 39.1% 0.001
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Gene  expression  profiles  were  correlated  with  the
presence of distant metastases. muc-1 overexpression
was  significantly  related  to  metastatic  disease  (p  =
0.025). Furthermore, 4 out of 5 patients overexpress-
ing mgb1 presented with distant metastases (p = 0.018).
Finally,  the  gene  profiles  ga733.2/muc-1 (p  =  0.018)
and ga733.2/muc-1/spdef /mgb1 (p = 0.046) significantly
correlated with advanced disease (Table 3). 
CORRELATION TO Ca 15-3 STATUS
The gene expression data were also compared with
ELISA-determined  Ca  15-3 serum  levels.  Ca  15-3
could  not  be  determined  in  4  cases.  Positive  single
gene and gene pattern strongly correlated with Ca 15-
3 positive  cases.  Statistical  analyses  revealed  highly-
significant  results  for  all  genes  and  gene  patterns
(Table 4).
EUROPEAN JOURNAL OF MEDICAL RESEARCH August 12, 2009 361
Table 2. Correlation to nodal status. Correlation between gene expression and nodal status.  Patients were stratified in groups
N0, N1 and N2 or higher. Simple and twofold positivity of the gene profile ga733.2/muc-1/mgb1/spdef are shown (Pearson’s bi-
variate correlation).
Analyzed gene Nodal status p-value 
N0 N1 >  N2
g ga a7 73 33 3. .2 2 1/28 4/19 3/12
3.6% 21.1% 25% 0.042
m mu uc c- -1 1 2/28 3/19 4/12
7.1% 15.8% 33.3% 0.039
s sp pd de ef f 1/27 3/18 2/10
3.7% 16.7% 20% 0.107
m mg gb b1 1 2/26 2/17 0/9
7.7% 11.8% % 0.640
g ga a7 73 33 3. .2 2/m mu uc c- -1 1 2/28 5/19 4/12
7.1% 26.3% 33.3% 0.034
simple positive 5/26 5/12 4/9
19.2% 41.7% 44.4% 0.143
twofold positive 1/26 5/17 3/9
3.8% 29.4% 33.3% 0.016
Table 3. Correlation to distant metastases. Correlation between gene expression and distant metastases.  Patients were stratified
in groups M0 or M1. Simple and twofold positivity of the gene profile ga733.2/muc-1/mgb1/spdef are shown (Pearson’s bivariate
correlation).
Analyzed gene Presence of distant metastases p-value
M0 M1
g ga a7 73 33 3. .2 2 4/44 4/19
9.1% 21.1% 0.197
m mu uc c- -1 1 4/44 6/19
9.1% 31.6% 0.025
s sp pd de ef f 3/39 4/19
7.7% 21.1% 0.148
m mg gb b1 1 1/37 4/18
2.7% 22.2% 0.018
g ga a7 73 33 3. .2 2/m mu uc c- -1 1 5/44 7/19
11.4% 36.8% 0.018
simple positive 7/37 8/18
18.9% 44.4% 0.046
twofold positive 4/37 6/18
10.8% 33.3% 0.063
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Haematological dissemination of malignant cells is a
prerequisite to distant organ metastases in many can-
cer  entities  [21-24].  Yet,  several  studies  suggest  that
only a minority of tumour cells have the ability to in-
vade and metastasize [17-19]. Therefore, it is crucial to
investigate which genes ultimately facilitate tissue inva-
sion and disease progression. 
Here, we propose an association between a certain
set of genes (ga733.2, muc-1, mgb1 and spdef) and ad-
vanced tumour stages in BC. Notably, the studied gene
signature exposed a significant correlation with stage
levels IIIa or higher. Herein, muc-1 expression signifi-
cantly  correlated  with  nodal  and  distant  metastases,
and hence higher staging levels. In line with these re-
sults, it has been recently shown that a muc-1-induced
tumourigenesis gene signature could predict disease-
free and overall survival in patients with breast and
lung cancer [20]. 
All investigated genes and gene profiles were signif-
icantly correlated with Ca 15-3 positivity. Since elevat-
ed levels of this tumour marker have been shown to
predict the outcome in BC, the gene signature we ana-
lyzed is likely to hold prognostic relevance.
The present investigation poses several questions:
First,  since  the  analyses  was  not  performed  in  a
prospective  manner,  it  is  impossible  to  determine
whether the detected gene profiles in patients with late
disease might also be present in early stages of the dis-
ease. Second, it remains to be studied whether CTC
exhibit a daily or hourly fluctuation in the gene expres-
sion levels. This could lead to false negative results in
the proposed method. 
In summary, our data indicate a notable correlation
between the studied genes (ga733.2, muc-1, mgb1 and
spdef)  and  advanced  disease  in  BC.  Accordingly,  the
studied  genes  might  play  a  role  in  the  process  of
metastases formation. However, prospective studies in
a larger patient population are needed to further vali-
date the proposed hypothesis.
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